Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan So

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Active surveillance is the preferred approach to clinical stage I testicular cancerCraig R Nichols, Bruce Roth, Peter Albers, et al.
BJU International|February 9, 2019
Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trialMihir Desai, Mo Bidair, Kevin C Zorn, et al.
The Journal of Urology|September 10, 2025
Reply by AuthorsBernhard J Eigl, Arun Elangovan, Sunita Ghosh, et al.
BJU International|April 26, 2018
WATER II (80-150 mL) procedural outcomesMihir Desai, Mo Bidair, Naeem Bhojani, et al.
The Journal of Urology|July 25, 2025
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME StudyBernhard J Eigl, Arun Elangovan, Sunita Ghosh, et al.
Urology|May 7, 2019
Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year ResultsNaeem Bhojani, Mohamed Bidair, Kevin C Zorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2019
Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy SpectrumLucia Nappi, Marisa Thi, Amy Lum, et al.
BJUI Compass|April 27, 2022
Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial resultsKevin C Zorn, Mohamed Bidair, Andrew Trainer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 3, 2011
RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancerShaguna Seth, Yoshiyuki Matsui, Kathy Fosnaugh, et al.
The Journal of Urology|May 18, 2019
Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical CystectomyKristen McAlpine, Luke T Lavallée, Dawn Stacey, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Active surveillance is the preferred approach to clinical stage I testicular cancerCraig R Nichols, Bruce Roth, Peter Albers, et al.
BJU International|February 9, 2019
Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trialMihir Desai, Mo Bidair, Kevin C Zorn, et al.
The Journal of Urology|September 10, 2025
Reply by AuthorsBernhard J Eigl, Arun Elangovan, Sunita Ghosh, et al.
BJU International|April 26, 2018
WATER II (80-150 mL) procedural outcomesMihir Desai, Mo Bidair, Naeem Bhojani, et al.
The Journal of Urology|July 25, 2025
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME StudyBernhard J Eigl, Arun Elangovan, Sunita Ghosh, et al.
Urology|May 7, 2019
Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year ResultsNaeem Bhojani, Mohamed Bidair, Kevin C Zorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2019
Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy SpectrumLucia Nappi, Marisa Thi, Amy Lum, et al.
BJUI Compass|April 27, 2022
Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial resultsKevin C Zorn, Mohamed Bidair, Andrew Trainer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 3, 2011
RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancerShaguna Seth, Yoshiyuki Matsui, Kathy Fosnaugh, et al.
The Journal of Urology|May 18, 2019
Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical CystectomyKristen McAlpine, Luke T Lavallée, Dawn Stacey, et al.
Pageof 13